Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sunesis Pharmaceuticals
Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the blood) and determining the dose and dose schedule for the next phase of studies with SNS-595.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must give written informed consent
18 years of age
Advanced solid malignant tumors
Tumor can be measured and evaluated
Blood tests are within standard limits
Normal blood coagulation
ECOG Performance Status equal to 0 or 1
You may not be if
Pregnant or breastfeeding.
Women of childbearing potential unwilling to use an approved, effective means of contraception according to the institution's standards.
Heart attack, stroke/TIA or other blood clotting event (deep vein thrombosis or pulmonary embolus) within 6 months before the screen visit.
Requires kidney dialysis (hemodialysis or peritoneal).
Known bleeding disorder (ie, hemophilia, von Willebrand Disease, coagulopathy, etc.).
Received an investigational agent or prior chemotherapy or immunotherapy within 28 days before first dose of SNS-595
Currently receiving corticosteroids (inhaled steroids for breathing diseases are allowed) or seizure medications.
Any medical, psychological, or social condition that, in the opinion of the Principal Investigator, would contraindicate the patient's participation in the clinical trial due to safety and or compliance with study procedures.
Clareo Health | Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
